LIBMYRIS

This brand name is authorized in Austria, Estonia, France, Croatia, Ireland, Lithuania, Poland

Active ingredients

The drug LIBMYRIS contains one active pharmaceutical ingredient (API):

1 Adalimumab UNII FYS6T7F842 - ADALIMUMAB

Adalimumab binds specifically to TNF and neutralizes the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 0.1-0.2 nM). Read about Adalimumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LIBMYRIS 40 mg Solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC
LIBMYRIS 80 mg Solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L04AB04	Adalimumab	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AB Tumor necrosis factor alpha (TNF-α) inhibitors
Discover more medicines within L04AB04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1866528, 1866539, 1866540, 1866551, 1866562, 1866573
Country: FR	Base de données publique des médicaments	Identifier(s): 63098253, 64680655, 65973337
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1093665, 1093666, 1093667, 1093668, 1093669, 1093670, 1093671
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100460471